Liraglutide to Improve corONary Haemodynamics During Exercise streSS

NCT02315001 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can improve heart function during exercise in people with stable angina or coronary heart disease.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind study

Participants 26 people

Who can join Ages 18–80 · all sexes

Timeline Started 2014-01 · est. completion 2015-03

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT02315001 ↗

Description as written by the study sponsor.

A single-centre double-blind placebo-controlled crossover randomised controlled trial to determine the physiological basis of glucagon-like peptide-1 receptor activation on exercise haemodynamics, as manifest through specific electrophysiological parameters measured by serial exercise stress testing, in those patients with reversible myocardial ischaemia and obstructive coronary artery disease confirmed by a baseline exercise test and coronary angiography respectively.

Treatments tested

Liraglutide also known as Victoza Drug

GLP-1 receptor agonist administered via subcutaneous injection
Placebo Other

Volume-matched normal saline placebo administered via subcutaneous injection

Main thing measured	Change in rate pressure product at 0.1 mV ST-segment depression
Sponsor	King's College London
Conditions studied	Ischaemic Heart Disease, Coronary Heart Disease, Chronic Stable Angina
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02315001 ↗